Cerus (CERS) Asset Writedowns and Impairment (2010 - 2023)

Cerus (CERS) posted Asset Writedowns and Impairment of $1.5 million for Q3 2023, up 375.46% sequentially from -$542000.0 in Q4 2022.

Cerus (CERS) Asset Writedowns and Impairment (2010 - 2023) Analysis & Trends

Cerus has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $1.5 million in Q3 2023.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.5 million in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $951000.0 (changed N/A YoY) and the FY2023 annual result came in at $1.7 million, changed N/A from the prior year.
Asset Writedowns and Impairment improved to $1.5 million in Q3 2023 per CERS's latest filing, from -$542000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $1.5 million in Q3 2023 and troughed at -$542000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn

Download Data